RTI’s Silver Lining: Sterling Bone Void Approval Sends Stock Up 21% In August
This article was originally published in The Gray Sheet
Executive Summary
Regeneration Technologies' receipt of FDA clearance for the Sterling xenograft bone void fillers helped push the firm's stock price up 21% to $9.25 in August